Results 31 to 40 of about 212,897 (265)

What is the role of CRP in glioblastoma?

Cancer Treatment and Research Communications, 2021
Background: Glioblastoma is the most common primary malignant brain tumor in adults. Previous studies have suggested that CRP (C-reactive protein) could serve as a biomarker candidate as well as a prognostic factor in glioblastoma patients, and we here ...
Karolina Förnvik, Aida Maddahi, Emma Liljedahl, Kurt Osther, Leif G. Salford, Henrietta Nittby Redebrandt   +5 more
doaj   +1 more source

Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity

Brain, Behavior, & Immunity - Health
Immuno-oncology, specifically immune checkpoint inhibitors (ICIs), has revolutionized cancer care with dramatic, long-term responses and increased survival, including patients with metastatic cancer to the brain.
Steven Brem
doaj   +1 more source

Angiogenesis in Glioblastoma [PDF]

New England Journal of Medicine, 2013
Recent work suggests that glioblastoma cells can differentiate into endothelial cells and pericytes, thus providing a means of tumor vascularization.
Sunit, Das, Philip A, Marsden
openaire   +2 more sources

Treatment of Glioblastoma [PDF]

Journal of Oncology Practice, 2017
Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity. Despite ongoing research, there has not been improvement in survival in glioblastoma.
Joo Yeon, Nam, John F, de Groot
openaire   +2 more sources

The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ‐dependent inhibition of the AKT pathway

EMBO Molecular Medicine, 2016
A variety of drugs targeting monoamine receptors are routinely used in human pharmacology. We assessed the effect of these drugs on the viability of tumor‐initiating cells isolated from patients with glioblastoma.
Suzana Assad Kahn, Silvia Lima Costa, Sharareh Gholamin, Ryan T Nitta, Luiz Gustavo Dubois, Marie Fève, Maria Zeniou, Paulo Lucas Cerqueira Coelho, Elias El‐Habr, Josette Cadusseau, Pascale Varlet, Siddhartha S Mitra, Bertrand Devaux, Marie‐Claude Kilhoffer, Samuel H Cheshier, Vivaldo Moura‐Neto, Jacques Haiech, Marie‐Pierre Junier, Hervé Chneiweiss   +18 more
doaj   +1 more source

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy

Journal of Experimental & Clinical Cancer Research, 2021
Immunotherapy is currently under intensive investigation as a potential breakthrough treatment option for glioblastoma. Given the anatomical and immunological complexities surrounding glioblastoma, lymphocytes that infiltrate the brain to develop durable
Jorrit De Waele, Tias Verhezen, Sanne van der Heijden, Zwi N. Berneman, Marc Peeters, Filip Lardon, An Wouters, Evelien L. J. M. Smits   +7 more
doaj   +1 more source

The Glioblastoma CircularRNAome

International Journal of Molecular Sciences, 2023
Glioblastoma remains one of the most aggressive cancers of the brain, warranting new methods for early diagnosis and more efficient treatment options. Circular RNAs (circRNAs) are rather new entities with increased stability compared to their linear counterparts that interact with proteins and act as microRNA sponges, among other functions.
Alexandru Tirpe, Cristian Streianu, Stefana Maria Tirpe, Anja Kocijancic, Radu Pirlog, Bianca Pirlog, Constantin Busuioc, Ovidiu-Laurean Pop, Ioana Berindan-Neagoe   +8 more
openaire   +2 more sources

Abnormal Schwannoma-like Growth of multiple, multifocal BRAF V600E-positive Glioblastoma in the Interior Acoustic Canal with Leptomeningeal Infiltration: a case report

Journal of Medical Case Reports, 2022
Background Glioblastoma belongs to the most common and most aggressive tumor entity of the central nervous system with a poor prognosis of only few months.
Roopa Jayarama-Naidu, Evelyn Gallus
doaj   +1 more source

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma

Frontiers in Immunology, 2022
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades.
Paris M. Kollis, Paris M. Kollis, Lisa M. Ebert, Lisa M. Ebert, Lisa M. Ebert, John Toubia, Cameron R. Bastow, Rebecca J. Ormsby, Santosh I. Poonnoose, Santosh I. Poonnoose, Sakthi Lenin, Melinda N. Tea, Stuart M. Pitson, Stuart M. Pitson, Guillermo A. Gomez, Michael P. Brown, Michael P. Brown, Michael P. Brown, Tessa Gargett, Tessa Gargett, Tessa Gargett   +20 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source